Document is current
Any future updates will be listed below
-
Authors
Padilla, Brad
Shields, Alan L.
Taylor, Fiona https://orcid.org/0000-0001-6474-4314
Li, Xiaoran
Mcdonald, Jeffrey
Green, Tanya
Boral, Anthony L.
Lin, Hui-Min
Akin, Cem
Siebenhaar, Frank
Mar, Brenton
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03731260 at ClinicalTrials.govDocuments that mention this clinical trial
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study
https://doi.org/10.1186/s13023-021-02037-3
-
Funding
Funding for this research was provided by:
Blueprint Medicines
- License Information
-
More Information
Article History
Received: 21 May 2021
Accepted: 19 September 2021
First Online: 18 October 2021
Declarations
:
: Institutional review board or independent ethics committee approval was obtained from each study center that participated in NCT03731260. All patients gave written informed consent.
: Not applicable.
: BP, ALS, FT, XL, and JM are, or were at the time of the research, employees of Adelphi Values, which conducted research on behalf of Blueprint Medicines. TG, ALB, H-ML, and BM are employees of Blueprint Medicines and own stock in the company. CA received research funding and consultancy fees from Blueprint Medicines. FS is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Blueprint, Celldex, Genentech, Moxie, Novartis, and Uriach.
